Royalty Pharma (RPRX) Non Operating Interest Expenses (2019 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) Non Operating Interest Expenses (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Incyte | 25.57 Bn | 21.04 Bn | 1.57 Bn | 582,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 93.62 Mn |
| Mar 31, 2026 | 93.72 Mn |
| Dec 31, 2025 | 94.17 Mn |
| Sep 30, 2025 | 79.56 Mn |
| Jun 30, 2025 | 68.67 Mn |
| Mar 31, 2025 | 65.26 Mn |
| Dec 31, 2024 | 65.76 Mn |
| Sep 30, 2024 | 66.51 Mn |
| Jun 30, 2024 | 49.01 Mn |
| Mar 31, 2024 | 44.23 Mn |
| Dec 31, 2023 | 47.26 Mn |
| Sep 30, 2023 | 46.03 Mn |
| Jun 30, 2023 | 46.95 Mn |
| Mar 31, 2023 | 46.95 Mn |
| Dec 31, 2022 | 46.96 Mn |
| Sep 30, 2022 | 46.98 Mn |
| Jun 30, 2022 | 46.97 Mn |
| Mar 31, 2022 | 47.06 Mn |
| Dec 31, 2021 | 46.97 Mn |
| Sep 30, 2021 | 44.33 Mn |